Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 28, 2017, by Jazz Pharmaceuticals Plc (the "Company"). The report details a strategic operational change regarding the distribution of the Company's product, Xyrem (sodium oxybate) oral solution, in the United States.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the execution of a material definitive agreement and does not contain financial performance data.
Material Changes Versus Prior Period
- New Agreement: On June 28, 2017, Jazz Pharmaceuticals, Inc. entered into a Pharmacy Master Services Agreement with Express Scripts Specialty Distribution Services, Inc. ("Express Scripts").
- Scope: Express Scripts will provide exclusive distribution and customer/patient support services for Xyrem in the U.S.
- Termination: The new agreement terminates the Prior Master Services Agreement dated April 15, 2011, which involved Express Scripts and its affiliate, CuraScript, Inc.
- Effective Date: Both the new agreement and the termination of the prior agreement are effective July 1, 2017.
- Terms: The new agreement runs until June 30, 2019, with a one-year extension option for Jazz. Either party may terminate without cause with 180 days' prior written notice.
- Impact: The Company states there are no material changes to the rights and obligations between the new agreement and the prior agreement.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard terms of the distribution agreement. The agreement is billed monthly for services performed.
Key Facts for Investor Verification
- Verify the full text of the Master Services Agreement filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2017.
- Confirm the operational transition date of July 1, 2017, for the exclusive distribution of Xyrem.
- Monitor future filings for any financial impact resulting from the shift from a multi-party agreement (including CuraScript) to a direct agreement with Express Scripts.